Searched for
CIPLA NEW VENTURES
These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Ahead of Market: 10 things that will decide stock market action on ThursdayNifty 50 and BSE Sensex declined, snapping a three-day rally due to IT and FMCG losses. Rising India VIX signaled caution, though broader t...
- Engrail Therapeutics raises $157 million in funding from F-Prime Capital, othersThe proceeds of the fund raise will help to support advancement of Engrail’s pipeline for neuropsychiatric and neurodevelopmental disorders
- Samina Hamied of Cipla steps down from her executive roleSamina Hamied, executive vice-chairperson of Cipla, announced her decision to step down from her executive role due to personal and family ...
- Cipla appoints Peter Lankau as independent directorLankau is currently a principal of Lankau Consulting LLC. He serves on the Board of Directors of ANI Pharmaceuticals Inc and Phosphagenics ...
- Cipla divests 16.7 per cent stake in Chase Pharma to AllerganChase was recently financed by a Series B consortium consisting of New Rhein Healthcare, Edmond de Rothschild Investment Partners and Cipla...
- Cipla names Samina Vaziralli as Executive Vice-ChairmanVaziralli, daughter of MK Hamied -- the company's non-executive VC - has been a part of the core leadership team since joining the Mumbai-b...
- Stempeutics research gets DCGI nod for stem cell based productThe company's goal is to globalise Stempeucel for Buerger's Disease and the market size is approximately $ 1.5 billion worldwide.
- Cipla to sell entire stake in Biomab Holding for $25,775,000Drug major Cipla has entered into an agreement to sell its entire stake in Biomab Holding to Biomab Brilliant for a consideration of $25,77...
- Cipla inks pact with Biopharma SPA to establish joint venture in AlgeriaCipla has inked a pact with Biopharma SPA for establishing a joint venture company in Algeria to manufacture and market respiratory product...
- Fidelity Growth Partners invests in Cipla’s newly launched consumer healthcare businessFidelity Growth Partners & Fidelity Biosciences have invested an undisclosed sum in Mumbai based Cipla’s newly floated consumer healthcare ...
- Fidelity invests in Cipla’s consumer healthcare businessFidelity Growth Partners India and Fidelity Biosciences have invested an undisclosed sum in Indian drug maker Cipla’s newly floated consume...
- Cipla inducts Samina Vaziralli, chairman YK Hamied's niece to company's boardSamina Vaziralli, niece of Cipla Chairman YK Hamied, was appointed to the company's board on Thursday, thus inducting the next generation.
- Cipla elevates Samina Vaziralli to its boardCipla today announced the appointment of Samina Vaziralli as executive director on its board, paving way for a bigger role for her.
- Cipla's Stempeutics gets process patent for Stempeucel from JapanStempeutics has received process patent from the Japan for novel stem cell drug Stempeucel aimed at treatment of critical limb ischemia.
- Stempeutics' Stempeucel gets Orphan Drug status in EuropeAn orphan designation allows a company to benefit from incentives from the European Union to develop a medicine for a rare disease.
- Stempeutics gets EMA approval to market stem cell drug in EUThe ATMP classification, approved by the committee for Advanced Therapies (CAT) of the EMA will allow the Bengaluru- based Stempeutics to c...
- Cipla to form joint venture with Biopharm SPA for respiratory productsCipla has entered into an agreement with Biopharm SPA to form a joint venture company in Algeria to manufacture and market respiratory prod...
- Cipla floats in-house venture capital firmCipla's new initiative comes at a time when the company is making bold moves in expanding its international business.
Load More
